Literature DB >> 11837705

Modeling the pharmacokinetics and pharmacodynamics of a unique oral hypoglycemic agent using neural networks.

Sam H Haidar1, Steven B Johnson, Michael J Fossler, Ajaz S Hussain.   

Abstract

PURPOSE: To develop a predictive population pharmacokinetic/ pharmacodynamic (PK/PD) model for repaglinide (REP), an oral hypoglycemic agent, using artificial neural networks (ANNs).
METHODS: REP, glucose concentrations, and demographic data from a dose ranging Phase 2 trial were divided into a training set (70%) and a test set (30%). NeuroShell Predictor was used to create predictive PK and PK/PD models using population covariates: evaluate the relative significance of different covariates; and simulate the effect of covariates on the PK/PD of REP. Predictive performance was evaluated by calculating root mean square error and mean error for the training and test sets. These values were compared to naive averaging (NA) and randomly generated numbers (RN).
RESULTS: Covariates found to have an influence on PK of REP include dose, gender. race, age, and weight. Covariates affecting the glucose response included dose, gender, and weight. These differences are not expected to be clinically significant.
CONCLUSIONS: We came to the following three conclusions: 1) ANNs are more precise than NA and RN for both PK and PD; 2) the bias was acceptable for ANNs as compared with NA and RN; and 3) neural networks offer a quick and simple method for predicting, for identifying significant covariates, and for generating hypotheses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11837705     DOI: 10.1023/a:1013611617787

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  13 in total

1.  Application of neural computing in pharmaceutical product development.

Authors:  A S Hussain; X Q Yu; R D Johnson
Journal:  Pharm Res       Date:  1991-10       Impact factor: 4.200

2.  Artificial neural networks applied to the in vitro-in vivo correlation of an extended-release formulation: initial trials and experience.

Authors:  J A Dowell; A Hussain; J Devane; D Young
Journal:  J Pharm Sci       Date:  1999-01       Impact factor: 3.534

3.  Artificial neural networks as a novel approach to integrated pharmacokinetic-pharmacodynamic analysis.

Authors:  J V Gobburu; E P Chen
Journal:  J Pharm Sci       Date:  1996-05       Impact factor: 3.534

4.  Application of artificial neural networks (ANN) in the development of solid dosage forms.

Authors:  J Bourquin; H Schmidli; P van Hoogevest; H Leuenberger
Journal:  Pharm Dev Technol       Date:  1997-05       Impact factor: 3.133

5.  Neural network modeling for estimation of the aqueous solubility of structurally related drugs.

Authors:  J Huuskonen; M Salo; J Taskinen
Journal:  J Pharm Sci       Date:  1997-04       Impact factor: 3.534

6.  Application of neural networks to pharmacodynamics.

Authors:  P Veng-Pedersen; N B Modi
Journal:  J Pharm Sci       Date:  1993-09       Impact factor: 3.534

7.  Feasibility of developing a neural network for prediction of human pharmacokinetic parameters from animal data.

Authors:  A S Hussain; R D Johnson; N N Vachharajani; W A Ritschel
Journal:  Pharm Res       Date:  1993-03       Impact factor: 4.200

8.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

9.  Application of neural networks to population pharmacokinetic data analysis.

Authors:  H H Chow; K M Tolle; D J Roe; V Elsberry; H Chen
Journal:  J Pharm Sci       Date:  1997-07       Impact factor: 3.534

10.  Neural network predicted peak and trough gentamicin concentrations.

Authors:  M E Brier; J M Zurada; G R Aronoff
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

View more
  3 in total

1.  Population pharmacokinetic and pharmacodynamic models of remifentanil in healthy volunteers using artificial neural network analysis.

Authors:  S H Kang; M R Poynton; K M Kim; H Lee; D H Kim; S H Lee; K S Bae; O Linares; S E Kern; G J Noh
Journal:  Br J Clin Pharmacol       Date:  2007-02-23       Impact factor: 4.335

Review 2.  Integrated pharmacokinetics and pharmacodynamics in drug development.

Authors:  Jasper Dingemanse; Silke Appel-Dingemanse
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 3.  A comprehensive review of integrative pharmacology-based investigation: A paradigm shift in traditional Chinese medicine.

Authors:  Haiyu Xu; Yanqiong Zhang; Ping Wang; Junhong Zhang; Hong Chen; Luoqi Zhang; Xia Du; Chunhui Zhao; Dan Wu; Feng Liu; Hongjun Yang; Changxiao Liu
Journal:  Acta Pharm Sin B       Date:  2021-03-20       Impact factor: 11.413

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.